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group. For example, there was no increase in prevalence of
infection in children by age. The non-response rate in the
survey was high because 29% of the listed visiting points and
37% of eligible respondents in the remaining households did
not participate. The survey results are questionable in other
ways; prevalence among children by race is the opposite of that
shown by other surveillance and death registration data, and
the HIV-1 pattern by provinces in the survey was also
inconsistent with surveillance and previous research. The
survey also provides no evidence that AIDS is nearly as
important a cause of mortality among children and teenagers
as the survey numbers would suggest. 
When the Gisselquist group’s first set of papers came out,
they were reported by the world’s media somewhat
uncritically as evidence that unsafe sex was not the primary
mode of transmission of HIV-1 transmission in sub-Saharan
Africa. Already, the US Senate Committee on Health,
Education, Labor and Pensions have held hearings to decide
whether HIV/AIDS funds should be devoted to programmes
that target unsafe injections rather than unsafe sex. The danger
of taking Gisselquist’s research in an uncritical way is that it
may lead to a reduction in the impact of the message that
unsafe sex transmits HIV-1 — something for which the
evidence is compelling if examined carefully and
systematically. That is not to say that we should take no notice
of the documented problems around the re-use of disposable
syringes. But the emphasis should be placed purely on
ensuring sterile technique, and scarce resources should not be
devoted to research into the extent of nosocomial transmission
of HIV-1.
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Today, following a few decades of manufacturing advances, an
expanding range of insulin preparations is being used to meet
the short-acting and basal requirements of patients with
diabetes.
Because of the frequently dangerous confusion caused by
innumerable products on the world’s markets, with their
different concentrations, brand names, haphazard and
unmatching colour codes and alternative delivery devices —
made worse by the recent availability of a whole family of new
insulin analogues — the International Diabetes Federation and
the World Health Organisation (WHO) have long advocated a
uniform system of international product recognition on a
universal scale to minimise therapeutic errors known to
happen frequently.1
As from now South Africa will start to benefit from this
initiative in which all players, including all major insulin
manufacturers, fulfil a responsible role for the common good of
the world’s diabetic community. Thankfully we are already a
single-strength market following the successful changeover to
the U-100 insulins 20 years ago.2
For the greater safety of our patients we now have to
endorse the universal colour code for the four most frequently
prescribed human insulin ranges, namely regular/soluble,
NPH isophane, lente and biphasic 30/70 mixtures.3 This will
only apply to the multinational-sourced innovator insulins and
not to the possibly less effective generics that may one day
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reach our market. These four insulin ranges have been
assigned international individual colour codes (identified by
specific pantone colour numbers) now adhered to by all major
manufacturers (Table I). It was also unanimously agreed that
insulin manufacturers would not use the colour-coding
initiative in their marketing activities, nor would any single
company claim ownership of it.
All parties are still actively working together to produce a
colour code for insulin analogues, particularly as new long-
acting clear solutions — no longer cloudy suspensions — could
easily be mistaken for fast- or short-acting similarly clear
insulins.
The short-acting clear-looking regular/soluble range is
coded yellow, shared by the products Actrapid and Humulin
R. Their average time course of action is reasonably
reproducible and predictable, with onset in 30 minutes, peak 2
- 5 hours and duration 5 - 8 hours.
The most used intermediate/long-acting cloudy-looking
products belong to the NPH isophane range and are coded
light green, shared by Protaphane and Humulin N. Their time
action is fraught with large intra-individual variations in bio-
availability due to inconsistent subcutaneous absorption. On
average the onset of action is 1 - 3 hours, peak at 6 - 12 hours,
and duration 16 - 24 hours, but these may vary substantially
between patients, depending on the site and depth of injection
and the ability of patients to accurately re-suspend the cloudy
NPH insulin in syringes or pens before injection.
Also intermediate/long-acting and cloudy in appearance,
insulin preparations in the lente range, now coded turquoise
and comprising Monotard and Humulin L, are much less
frequently used nowadays as they suffer even more significant
pharmacokinetic limitations and inconsistent bio-availability.
Patients would benefit from being switched over to NPH
insulins instead, and for safety reasons these preparations
should eventually be withdrawn from use.
Biphasic 30/70 mixtures are now all coded brown and the
products available in this premixed range are Actraphane
30/70 and Humulin 30/70. These are cloudy fixed mixtures of
regular and NPH insulins with an average time course of
action, with onset in 30 minutes, peak at 2 - 12 hours and
duration 16 - 24 hours. They share with NPH insulins a
number of common disadvantages including inconsistent
absorption and the need for adequate re-suspension before
injection.
The large intra-individual and interpatient variations in bio-
availability are one of the most difficult aspects of insulin
treatment, making it difficult to plan dosing accurately.
Adequate instructions regarding pre-injection re-suspension
can make a difference of up to 50% in the effectiveness of
cloudy prolonged-action insulins.
The present worldwide strategy of universal colour coding
will facilitate product recognition, making it safer for health
care professionals and patients alike. The minor
pharmacokinetic differences between human insulins of
different sources of manufacture (i.e. Escherichia coli and yeast),
if any, are overshadowed by the large variability in absorption
which is shared by all cloudy insulins and is inherent to their
state of suspensions. Therapeutic product equivalence,
although never absolute, is as close as it has ever been before.
Patients can now be moved safely from one insulin brand to
another when circumstances of availability or price compel the
prescriber or dispenser to do so, from pens to syringes and
vials or vice versa, unit for unit, as long as the colour code
identification is respected (and the concentration is
standardised, which it is in South Africa). Patients for whom it
is deemed preferable to use a pen device, viz. those on a
multiple injection regimen, those with poor vision, arthritis, the
young, the elderly, should not be summarily switched to
syringes and vials without due consideration for their personal
circumstances. This would be a major retrogressive step which
could adversely influence their adherence to treatment and
quality of life.
The act of dispensing insulin will thus be made safer and
more educative, with opportunities for enhanced pharma-
covigilance regarding colour-code recognition, proper re-
suspension, recommenddations for storage, and emphasis on
dialing or drawing-up and injection techniques with the
specific delivery device prescribed.
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Table I. International colour code for human insulin preparations
Product group Product Colour name Colour*
Short-acting insulin Regular Yellow
Long-acting insulin NPH Isophane Light green
Lente Turquoise
Biphasic insulin Premixtures 30/70 Brown
*The colours illustrated here are approximate guidelines only.
